Acidic and basic drugs in medicinal chemistry: A perspective

Journal of Medicinal Chemistry

Volumn 57, Issue 23, 2014, Pages 9701-9717

  Charifson, Paul S ^a   Walters, W Patrick ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; ION; LEWIS ACID; LEWIS BASE; PROTEIN BINDING;

ACIDITY; CELLULAR DISTRIBUTION; DRUG DEVELOPMENT; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SAFETY; LIPOPHILICITY; MEDICINAL CHEMISTRY; PROTON TRANSPORT; REVIEW; SOLUBILITY; TISSUE DISTRIBUTION; ADVERSE DRUG REACTION; BIOAVAILABILITY; CHEMICAL DATABASE; CHEMISTRY; DRUG ADMINISTRATION ROUTE; HUMAN; KIDNEY; LIVER; METABOLISM; PERMEABILITY; PH; PHARMACOKINETICS;

BIOLOGICAL AVAILABILITY; DATABASES, CHEMICAL; DRUG ADMINISTRATION ROUTES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; IONS; KIDNEY; LEWIS ACIDS; LEWIS BASES; LIVER; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84918564366     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501000a     Document Type: Review

References (82)

1. Manallack, D. T.; Prankerd, R. J.; Yuriev, E.; Oprea, T. I.; Chalmers, D. K. The Significance of Acid/Base Properties in Drug Discovery Chem. Soc. Rev. 2012, 42, 485
2. Manallack, D. T. The pKa Distribution of Drugs: Application to Drug Discovery Perspect. Med. Chem. 2012, 1-23
3. Manallack, D. T. The Acid-Base Profile of a Contemporary Set of Drugs: Implications for Drug Discovery SAR QSAR Environ. Res. 2009, 20, 611-655
4. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of Ion Class and Time on Oral Drug Molecular Properties Med. Chem. Commun. 2011, 2, 91
5. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb J. Med. Chem. 2008, 51, 817-834
6. Meanwell, N. A. Improving Drug Candidates by Design: a Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety Chem. Res. Toxicol. 2011, 24, 1420-1456
7. Lesney, M. S. A Basic History of Acid-From Aristotle to Arnold. Todays Chemist at Work; American Chemical Society: Washington, DC, 2003; pp 47-48.
8. Kolb, D. Acids and Bases J. Chem. Educ. 2004, 459-464
9. Brittain, H. G. Strategy for the Prediction and Selection of Drug Substance Salt Forms. Pharm. Technol. 2007, (http://www.pharmtech.com/pharmtech/Formulation/Strategy-for-the-Prediction-and-Selection-of-Drug-/ArticleStandard/Article/detail/463704).
10. Stephenson, G. A.; Aburub, A.; Woods, T. A. Physical Stability of Salts of Weak Bases in the Solid-State J. Pharm. Sci. 2010, 100, 1607-1617
11. Waring, M. J.; Johnstone, C. A Quantitative Assessment of hERG Liability as a Function of Lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
12. Foyes Principles of Medicinal Chemistry, 7 th ed.; Lemke, T. L.; Williams, D. A.; Roche, V. F.; Zito, S. W., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2013; pp 67-69 and Appendix B.
13. Altan, N.; Chen, Y.; Schindler, M.; Simon, S. M. Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy J. Exp. Med. 1998, 187 (10) 1583-1598
14. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Strategy and Tactics for hERG Optimizations. Antitargets: Prediction and Prevention of Drug Side Effects; Wiley-VCH: Weinheim, Germany, 2008; Chapter 18, pp 423-455.
15. Notari, R. E.; Ed. Biopharmaceutics and Clinical Pharmacokinetics: An Introduction, 4 th ed.; Marcel Dekker: New York, 1987; pp 134-140.
16. Pagliara, A.; Reist, M.; Geinoz, S.; Carrupt, P. A.; Testa, B. Evaluation and Prediction of Drug Permeation J. Pharm. Pharmacol. 1999, 51 (12) 1339-1357
17. Cramariuc, O.; Rog, T.; Javanainen, M.; Monticelli, L.; Polishchuk, A. V.; Vattulainen, I. Mechanism for Translocation of Fluoroquinolones Across Lipid Membranes Biochim. Biophys. Acta, Biomembr. 2012, 1818, 2563-2571
18. Mazák, K.; Noszál, B. Zwitterions Can Be Predominant in Membrane Penetration of Drugs: Experimental Proof J. Med. Chem. 2012, 55, 6942-6947
19. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery Nucleic Acids Res. 2012, 40 (D1) D1100-D1107
20. Li, Q.; Cheng, T.; Wang, Y.; Bryant, S. H. PubChem as a Public Resource for Drug Discovery Drug Discovery Today 2010, 15 (23) 1052-1057
21. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug Discovery and Exploration Nucleic Acids Res. 2006, 34 (Suppl. 1) D668-D672
22. MarvinSketch, version 5.8; ChemAxon: Budapest, Hungary, 2012; http://www.chemaxon.com.
23. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2013; http://www.R-project.org/.
24. Varma, M. V. S.; Feng, B.; Obach, R. S.; Troutman, M. D.; Chupka, J.; Miller, H. R.; El-Kattan, A. Physicochemical Determinants of Human Renal Clearance J. Med. Chem. 2009, 52, 4844-4852
25. Testa, B/; Krämer, S. D. The Biochemistry of Drug Metabolism-An Introduction, Part 2. Redox Reactions and Their Enzymes Chem. Biodiversity 2007, 4, 257-405
26. Guha, R.; Dexheimer, T. S.; Kestranek, A. N.; Jadhav, A.; Chervenak, A. M.; Ford, M. G.; Simeonov, A.; Roth, G. P.; Thomas, C. J. Exploratory Analysis of Kinetic Solubility Measurements of a Small Molecule Library Bioorg. Med. Chem. 2011, 19, 4127-4134
27. Varma, M. V.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-Kattan, A.; Troutman, M. D. Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination J. Med. Chem. 2010, 53 (3) 1098-1108
28. Lombardo, F.; Obach, R. S.; Varma, M. V.; Stringer, R.; Berellini, G. Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models J. Med. Chem. 2014, 57, 4397-4405
29. Rodgers, T.; Rowland, M. Physiologically Based Pharmacokinetic Modelling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions J. Pharm. Sci. 2006, 95, 1238-1257
30. Yun, Y. E.; Edginton, A. N. Correlation-Based Prediction of Tissue-to-Plasma Partition Coefficients Using Readily Available Input Parameters Xenobiotica 2013, 43, 839-852
31. Yokogawa, K.; Ishizaki, J.; Ohkuma, S.; Miyamoto, K. Influence of Lipophilicity and Lysosomal Accumulation on Tissue Distribution Kinetics of Basic Drugs: A Physiologically Based Pharmacokinetic Model Methods Find. Exp. Clin. Pharmacol. 2002, 24 (2) 81-93
32. Ndolo, R. A.; Luan, Y.; Duan, S.; Forrest, M. L.; Krise, J. P. Lysosomotropic Properties of Weakly Basic Anticancer Agents Promote Cancer Cell Selectivity in Vitro PLoS One 2012, 7, e49366
33. Gerweck, L. E.; Seetharaman, K. Cellular pH Gradient in Tumor versus Normal Tissue: Potential Exploitation for the Treatment of Cancer Cancer Res. 1996, 56 (6) 1194-1198
34. Poulin, P.; Dambach, D. M.; Hartley, D. H.; Ford, K.; Theil, F.-P.; Harstad, E.; Halladay, J.; Choo, E.; Boggs, J.; Liederer, B. M.; Dean, B.; Diaz, D. An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters J. Pharm. Sci. 2013, 102, 3816-3829
35. Small, H.; Gardner, I.; Jones, H. M.; Davis, J.; Rowland, M. Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations To Predict Steady-State Volume of Distribution Drug Metab. Dispos. 2011, 39, 1789-1793
36. Ishizaki, J.; Yokogawa, K.; Nakashima, E.; Ohkuma, S.; Ichimura, F. Uptake of Basic Drugs into Rat Lung Granule Fraction in Vitro Biol. Pharm. Bull. 1998, 21 (8) 858-861
37. Bingham, M.; Rankovic, Z. Medicinal Chemistry Challenges in CNS Drug Discovery. In RSC Drug Discovery; Royal Society of Chemistry: Cambridge, U.K., 2012; Chapter 18, pp 465-509.
38. Yoshida, F.; Topliss, J. G. QSAR Model for Drug Human Oral Bioavailability 1 J. Med. Chem. 2000, 43, 2575-2585
39. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds ChemMedChem 2009, 4, 680-686
40. Karlgren, M.; Vildhede, A.; Norinder, U.; Wisniewski, J. R.; Kimoto, E.; Lai, Y.; Haglund, U.; Artursson, P. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions J. Med. Chem. 2012, 55 (10) 4740-4763
41. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural Alert/Reactive Metabolite Concept As Applied in Medicinal Chemistry To Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States Chem. Res. Toxicol. 2011, 24, 1345-1410
42. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
43. Poulin, P.; Ekins, S.; Theil, F.-P. A Hybrid Approach to Advancing Quantitative Prediction of Tissue Distribution of Basic Drugs in Human Toxicol. Appl. Pharmacol. 2011, 250, 194-212
44. Macintyre, A. C.; Cutler, D. J. The Potential Role of Lysosomes in Tissue Distribution of Weak Bases Biopharm. Drug Dispos. 1988, 9 (6) 513-526
45. Diaz, D.; Ford, K. A.; Hartley, D. P.; Harstad, E. B.; Cain, G. R.; Achilles-Poon, K.; Nguyen, T.; Peng, J.; Zheng, Z.; Merchant, M.; Sutherlin, D. P.; Gaudino, J. J.; Kaus, R.; Lewin-Koh, S. C.; Choo, E. F.; Liederer, B. M.; Dambach, D. M. Pharmacokinetic Drivers of Toxicity for Basic Molecules: Strategy to Lower pKa Results in Decreased Tissue Exposure and Toxicity for a Small Molecule Met Inhibitor Toxicol. Appl. Pharmacol. 2013, 266, 86-94
46. Tengstrand, E. A.; Miwa, G. T.; Hsieh, F. Y. Bis(monoacylglycerol)phosphate as a Non-Invasive Biomarker To Monitor the Onset and Time-Course of Phospholipidosis with Drug-Induced Toxicities Expert Opin. Drug Metab. Toxicol. 2010, 6, 555-570
47. Donato, M. T.; Gomez-Lechon, M. J. Drug-Induced Liver Steatosis and Phospholipidosis: Cell-Based Assays for Early Screening of Drug Candidates Curr. Drug Metab. 2012, 13 (8) 1160-1173
48. Bernstein, P. R.; Ciaccio, P.; Morelli, J. Drug-Induced Phospholipidosis, 1 st ed.; Elsevier Inc.: Amsterdam, 2011; Vol. 46, pp 419-430.
49. Ishizaki, J.; Yokogawa, K.; Nakashima, E. M. I.; Ichimura, F. Relationships between the Hepatic Intrinsic Clearance or Blood Cell-Plasma Partition Coefficient in the Rabbit and the Lipophilicity of Basic Drugs J. Pharm. Pharmacol. 1997, 49 (8) 768-772
50. Naven, R. T.; Swiss, R.; Klug-Mcleod, J.; Will, Y.; Greene, N. The Development of Structure-Activity Relationships for Mitochondrial Dysfunction: Uncoupling of Oxidative Phosphorylation Toxicol. Sci. 2013, 131, 271-278
51. Ng, D. S.; Maickel, R. P.; Borowitz, J. L. Subcellular Distribution of Weak Acids and Bases in Adrenal Medulla Gen. Pharmacol. 1982, 13 (1) 15-20
52. Upthagrove, A. L.; Nelson, W. L. Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Derivatives. Preparation, Identification of Metabolite Regioisomers, and Metabolism by CYP2D6 Drug Metab. Dispos. 2001, 29 (11) 1377-1388
53. Austin, R. P. The Binding of Drugs to Hepatocytes and Its Relationship to Physicochemical Properties Drug Metab. Dispos. 2004, 33, 419-425
54. Pedersen, J. M.; Matsson, P.; Bergstrom, C. A. S.; Hoogstraate, J.; Noren, A.; LeCluyse, E. L.; Artursson, P. Early Identification of Clinically Relevant Drug Interactions with the Human Bile Salt Export Pump (BSEP/ABCB11) Toxicol. Sci. 2013, 136, 328-343
55. De Bruyn, T.; van Westen, G. J. P.; IJzerman, A. P.; Stieger, B.; de Witte, P.; Augustijns, P. F.; Annaert, P. P. Structure-Based Identification of OATP1B1/3 Inhibitors Mol. Pharmacol. 2013, 83, 1257-1267
56. Ahlin, G.; Karlsson, J.; Pedersen, J. M.; Gustavsson, L.; Larsson, R.; Matsson, P.; Norinder, U.; Bergström, C. A. S.; Artursson, P. Structural Requirements for Drug Inhibition of the Liver Specific Human Organic Cation Transport Protein 1 J. Med. Chem. 2008, 51, 5932-5942
57. Zolk, O.; Solbach, T. F.; König, J.; Fromm, M. F. Structural Determinants of Inhibitor Interaction with the Human Organic Cation Transporter OCT2 (SLC22A2) Naunyn-Schmiedebers Arch. Pharmacol. 2008, 379, 337-348
58. Bergstrom, M. A.; Isin, E. M.; Castagnoli, N.; Milne, C. E. Bioactivation Pathways of the Cannabinoid Receptor 1 Antagonist Rimonabant Drug Metab. Dispos. 2011, 39, 1823-1832
59. Stachulski, A. V.; Meng, X. Glucuronides From Metabolites to Medicines: A Survey of the in Vivo Generation, Chemical Synthesis and Properties of Glucuronides Nat. Prod. Rep. 2013, 30, 806
60. Dragovic, S.; Gunness, P.; Ingelman-Sundberg, M.; Vermeulen, N. P. E.; Commandeur, J. N. M. Characterization of Human Cytochrome P450s Involved in the Bioactivation of Clozapine Drug Metab. Dispos. 2013, 41, 651-658
61. Doss, G. A.; Miller, R. R.; Zhang, Z.; Teffera, Y.; Nargund, R. P.; Palucki, B.; Park, M. K.; Tang, Y. S.; Evans, D. C.; Baillie, T. A.; Stearns, R. A. Metabolic Activation of a 1,3-Disubstituted Piperazine Derivative: Evidence for a Novel Ring Contraction to an Imidazoline Chem. Res. Toxicol. 2005, 18, 271-276
62. Stahly, G. P. Diversity in Single- and Multiple-Component Crystals: The Search for and Prevalence of Polymorphs and Cocrystals Cryst. Growth Des. 2007, 7, 1007-1026
63. Childs, S. L.; Stahly, G. P.; Park, A. The Salt-Cocrystal Continuum: The Influence of Crystal Structure on Ionization State Mol. Pharmaceutics 2007, 4, 323-338
64. Aakeröy, C. B.; Fasulo, M. E.; Desper, J. Cocrystal or Salt: Does It Really Matter? Mol. Pharmaceutics 2007, 4, 317-322
65. Sttippler, E.; Kopp, S.; Dressman, J. B. Comparison of US Pharmacopeia Simulated Intestinal Fluid TS (without Pancreatin) and Phosphate Standard Buffer pH 6.8, TS of the International Pharmacopoeia with Respect to Their Use in in Vitro Dissolution Testing Dissolution Technol. 2004, 11 (2) 6-11
66. Serajuddin, A. Salt Formation To Improve Drug Solubility Adv. Drug Delivery Rev. 2007, 59 (7) 603-616
67. Ravula, S. B.; Yu, J.; Tran, J. A.; Arellano, M.; Tucci, F. C.; Moree, W. J.; Li, B.-F.; Petroski, R. E.; Wen, J.; Malany, S.; Hoare, S. R. J.; Madan, A.; Crowe, P. D.; Beaton, G. Lead Optimization of 2-(Piperidin-3-yl)-1 H -benzimidazoles: Identification of 2-Morpholin- and 2-Thiomorpholin-2-yl-1 H -benzimidazoles as Selective and CNS Penetrating H1-Antihistamines for Insomnia Bioorg. Med. Chem. Lett. 2012, 22, 421-426
68. Morgenthaler, M.; Schweizer, E.; Hoffmann-Röder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Müller, K. Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities ChemMedChem 2007, 2, 1100-1115
69. Fish, L. R.; Gilligan, M. T.; Humphries, A. C.; Ivarsson, M.; Ladduwahetty, T.; Merchant, K. J.; OConnor, D.; Patel, S.; Philipps, E.; Vargas, H. M.; Hutson, P. H.; MacLeod, A. M. 4-Fluorosulfonylpiperidines: Selective 5-HT2A Ligands for the Treatment of Insomnia Bioorg. Med. Chem. Lett. 2005, 15, 3665-3669
70. Meloun, M.; Bordovská, S. Benchmarking and Validating Algorithms That Estimate pKa Values of Drugs Based on Their Molecular Structures Anal. Bioanal. Chem. 2007, 389, 1267-1281
71. Liao, C.; Nicklaus, M. C. Comparison of Nine Programs Predicting pKa Values of Pharmaceutical Substances J. Chem. Inf. Model. 2009, 49, 2801-2812
72. Settimo, L.; Bellman, K.; Knegtel, R. M. A. Comparison of the Accuracy of Experimental and Predicted pKa Values of Basic and Acidic Compounds Pharm. Res. 2013, 31, 1082-1095
73. Cruciani, G.; Milletti, F.; Storchi, L.; Sforna, G.; Goracci, L. In Silico pKa Prediction and ADME Profiling Chem. Biodiversity 2009, 6, 1812-1821
74. Kang, B. H.; Altieri, D. C. Compartmentalized Cancer Drug Discovery Targeting Mitochondrial Hsp90 Chaperones Oncogene 2009, 28, 3681-3688
75. Ling, D.; Park, W.; Park, S.-J.; Lu, Y.; Kim, K. S.; Hackett, M. J.; Kim, B. H.; Yim, H.; Jeon, Y. S.; Na, K.; Hyeon, T. Multifunctional Tumor pH-Sensitive Self-Assembled Nanoparticles for Bimodal Imaging and Treatment of Resistant Heterogeneous Tumors J. Am. Chem. Soc. 2014, 136, 5647-5655
76. Aspiotis, R.; Chen, A.; Cauchon, E.; Dubé, D.; Falgueyret, J.-P.; Gagné, S.; Gallant, M.; Grimm, E. L.; Houle, R.; Juteau, H.; Lacombe, P.; Laliberté, S.; Lévesque, J.-F.; MacDonald, D.; McKay, D.; Percival, M. D.; Roy, P.; Soisson, S. M.; Wu, T. The Discovery and Synthesis of Potent Zwitterionic Inhibitors of Renin Bioorg. Med. Chem. Lett. 2011, 21, 2430-2436
77. Peters, J.-U.; Lübbers, T.; Alanine, A.; Kolczewski, S.; Blasco, F.; Steward, L. Cyclic Guanidines as Dual 5-HT5A/5-HT7 Receptor Ligands: Optimising Brain Penetration Bioorg. Med. Chem. Lett. 2008, 18, 262-266
78. Arbuckle, W.; Baugh, M.; Belshaw, S.; Bennett, D. J.; Bruin, J.; Cai, J.; Cameron, K. S.; Claxton, C.; Dempster, M.; Everett, K.; Fradera, X.; Hamilton, W.; Jones, P. S.; Kinghorn, E.; Long, C.; Martin, I.; Robinson, J.; Westwood, P. 1 H -Imidazo[4,5- c ]pyridine-4-carbonitrile as Cathepsin S Inhibitors: Separation of Desired Cellular Activity from Undesired Tissue Accumulation through Optimization of Basic Nitrogen pKa Bioorg. Med. Chem. Lett. 2011, 21, 932-935
79. Furber, M.; Tiden, A.-K.; Gardiner, P.; Mete, A.; Ford, R.; Millichip, I.; Stein, L.; Mather, A.; Kinchin, E.; Luckhurst, C.; Barber, S.; Cage, P.; Sanganee, H.; Austin, R.; Chohan, K.; Beri, R.; Thong, B.; Wallace, A.; Oreffo, V.; Hutchinson, R.; Harper, S.; Debreczeni, J.; Breed, J.; Wissler, L.; Edman, K. Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate J. Med. Chem. 2014, 57, 2357-2367
80. Clark, M. P.; Ledeboer, M. W.; Davies, I.; Byrn, R. A.; Jones, S. M.; Perola, E.; Tsai, A.; Jacobs, M.; Nti-Addae, K.; Bandrage, U. K.; Boyd, M. J.; Bethiel, R. S.; Court, J. J.; Deng, H.; Duffy, J. P.; Dorsch, W. A.; Farmer, L. J.; Gao, H.; Gu, W.; Jackson, K.; Jacobs, D. H.; Kennedy, J. M.; Ledford, B.; Liang, J.; Maltais, F.; Murcko, M.; Wang, T.; Wannamaker, M. W.; Bennett, H. B.; Leeman, J. R.; McNeil, C.; Taylor, W. P.; Memmott, C.; Jiang, M.; Rijnbrand, R.; Bral, C.; Germann, U.; Nezami, A.; Zhang, Y.; Salituro, F. G.; Bennani, Y. L.; Charifson, P. S. The Discovery of VX-787: A Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor of Influenza PB2 J. Med. Chem. 2014, 57 (15) 6668-6678
81. Sweetana, S.; Akers, M. J. Solubility Principles and Practices for Parenteral Drug Dosage Form Development PDA J. Pharm. Sci. Technol. 1996, 50 (5) 330-342
82. Kell, D. B.; Dobson, P. D.; Oliver, S. G. Pharmaceutical Drug Transport: The Issues and the Implications That It Is Essentially Carrier-Mediated Only Drug Discovery Today 2011, 16 (15) 704-714